Term
| Hypersensitivity Type I Description |
|
Definition
|
|
Term
| Hypersensitivity Type II Description |
|
Definition
| Antibody-mediated, autoimmune |
|
|
Term
| Hypersensitivity Type III Description |
|
Definition
| Immune complex-mediated, SLE |
|
|
Term
| Hypersensitivity Type IV Description |
|
Definition
| Cell-mediated, contact dermatitis, MS |
|
|
Term
| Hypersensitivity Type I Mechanism |
|
Definition
| IgE antibody, Th2, Mast cells |
|
|
Term
| Hypersensitivity Type II Mechanism |
|
Definition
| IgG, IgM, Phagocytosis, lysis |
|
|
Term
| Hypersensitivity Type III Mechanism |
|
Definition
| Antigen-antibody complex deposition, inflammation, necrosis |
|
|
Term
| Hypersensitivity Type IV Mechanism |
|
Definition
| Perivascular cellular infiltrates, activated T lymphocytes, cytokines, cytotoxicity, Th1, Th17, CTLs |
|
|
Term
|
Definition
| Allergy, Activates complement 3a/5a. IL-8, mellitin, codeine, adenosine. Th2 cells are vital |
|
|
Term
|
Definition
| vasodilation, vascular leakage, spasm, secretions |
|
|
Term
|
Definition
| 2-24 hours. Infiltration, tissue destruction |
|
|
Term
| Th2 cell cytokines for development |
|
Definition
|
|
Term
|
Definition
| B cell stimulation to IgE |
|
|
Term
|
Definition
| development and activation of eosinophils. Most potent known |
|
|
Term
|
Definition
| enhances IgE production and stimulates epithelial mucus secretion |
|
|
Term
|
Definition
| avidly binds IgE antibodies on mast cells and basophils, sensitizing them to the antibody's target |
|
|
Term
|
Definition
| Most potent vasoactive and spasmogenic agents known |
|
|
Term
|
Definition
| highly chemotactic for neutrophils, eosinophils and monocytes |
|
|
Term
|
Definition
| intense bronchospasm as well as increased mucus secretion |
|
|
Term
|
Definition
| Platelet activating factor |
|
|
Term
| Platelet Activating Factor |
|
Definition
| causes platelet aggregation, release of histamine, bronchospasm, increased vascular permeability, vasodilation |
|
|
Term
|
Definition
| Type I reaction to non-chemical stimuli such as temperature extremes and exercise |
|
|
Term
|
Definition
| antibodies react on cell surfaces or in the extracellular matrix. Complement and Fc receptor dependent inflammation. Myasthenia gravis, graves disease |
|
|
Term
|
Definition
| Antibody-dependent cellular cytotoxicity |
|
|
Term
| antibody-dependent cellular cytotoxicity |
|
Definition
| cells coated with antibody are killed by a variety of effector cells. Includes transfusion reactions, erythroblastosis fetalis, autoimmune hemolytic anemia, agranulocytosis, thrombocytopenia, hapten drugs |
|
|
Term
| Type III hypersensitivity |
|
Definition
| acute necrotizing vasculitis, fibrinoid necrosis, smudgy eosinophilic deposit, SLE. Includes acute serum sickness |
|
|
Term
| Type III hypersensitivity phase I |
|
Definition
| Formation of Immune complexes, about a week after injection of the protein |
|
|
Term
| Type III hypersensitivity phase II |
|
Definition
| Deposition of Immune Complexes. major influences are characteristics of complexes and local vascular alterations. ogten glomeruli and joints |
|
|
Term
| Type III hypersensitivity phase III |
|
Definition
| Tissue Injury. Acute inflammatory reaction. 10 days after antigen administration. fever, urticaria, arthralgias, lymph node enlargement, proteinuria. vasculitis, glomerulonephritis, arthritis. Serum C3 decreased. |
|
|
Term
|
Definition
| Local Immune complex disease. intracutaneous injection of antigen. Complexes precipitate on vessel walls with superimposed thrombosis |
|
|
Term
|
Definition
| antigen-avtivated (sensitized) T lymphocytes including CD4+/8+. Includes DTH. Activated macrophages transform into epithelioid cells, granulomatous inflammation |
|
|
Term
|
Definition
| Delayed-type hypersensitivity |
|
|
Term
| Delayed-type hypersensitivity |
|
Definition
| includes tuberculin reaction and contact dermatitis |
|
|
Term
|
Definition
| autocrine growth factor of antigen-responsive T cells |
|
|
Term
|
Definition
| Inflammatory cytokine. Secreted by IFN-gamma activated magrophages. Pyrogenic |
|
|
Term
|
Definition
| induces differentiation of CD4+ T-cells into the Th1 subset. Produced by activated macrophages. |
|
|
Term
|
Definition
| Promotes Th1 development. Activates macrophages. DTH response |
|
|
Term
|
Definition
| cytokines that recruit neutrophils and monocytes. Produced by Th17 cells |
|
|
Term
|
Definition
| Produced by activated Th17 cells. Amplifies Th17 response. |
|
|
Term
|
Definition
| Close relative of IL-12. Inflammatory cytokine |
|
|
Term
| Th17 differentiation promoters |
|
Definition
| IL-1, IL-6, IL-21, IL-23, TGF-beta |
|
|
Term
|
Definition
| self-reactive cells are killed in lymphoid organs. Receptor editing occurs often. |
|
|
Term
|
Definition
| autoimmune regulator. stimulates expression of peripheral tissue restricted self-antigens in the thymus. |
|
|
Term
|
Definition
| prolonged and irreversible functional inactivation of lymphocytes |
|
|
Term
|
Definition
| Anergy when costimulators are not available with antigens. Suppression by regulatory T cells. Deletion by activation-induced cell death |
|
|
Term
|
Definition
| CD25+, develop in the thymus, Mutations in Foxp3 break. |
|
|
Term
|
Definition
| Immune dysrelugation, polyendocrinopathy, enteropathy, X-linked. Mutations in the Foxp3 gene that breaks regulatory T-cells. |
|
|
Term
|
Definition
| self-reactive cells receive apoptotic signal through Fas-Fas ligand system and Bim. |
|
|
Term
| Autoimmune lymphoproliferative disease |
|
Definition
| Mutations in the FAS gene because deletion cannot occur |
|
|
Term
| Autoimmune susceptibility genes |
|
Definition
| PTPN-22, NOD-2, IL-2 receptor (CD25), IL-7 receptor chains. AIRE, CTLA4, PD1, FAS, FASL |
|
|
Term
|
Definition
| As an autoimmune disease matures it will recognize wider versions of it's target. |
|
|
Term
|
Definition
| More neutrophils with the monocytes than seen in Th1 response. |
|
|
Term
|
Definition
| Systemic Lupus Erythromatosus |
|
|
Term
| Systemic Lupus Erythromatosus |
|
Definition
| Type III, LE cells, Kidneys, blood, arthritis, HLA-DQ. Butterfly rash, spenomegaly, relapsing fevers, photosensitivity, pleuritic chest pain, hypocomplementemia |
|
|
Term
| Mesangial lupus glomerulonephritis |
|
Definition
| Most mild form. mesangial cell proliferation |
|
|
Term
| Focal proliferative glomerulonephritis |
|
Definition
| second type, may progress to diffuse |
|
|
Term
| Diffuse proliferative glomerulonephritis |
|
Definition
| Most severe. cellular crescents, hematuria as well as proteinuria |
|
|
Term
| Membranous glomerulonephritis |
|
Definition
| diffuse thickening of capillary walls. nephrotic syndrome. wire loop lesion |
|
|
Term
| Chronic Discoid Lupus Erythromatosis |
|
Definition
| Skin manifestations only. malar rash, urticaria, bullae, maculopapular lesions. Only rare dsDNA antibodies. |
|
|
Term
| Subacute Cutaneous Lupus Erythromatosis |
|
Definition
| skin involvement. widespread, superficial, nonscarring. SS-A antigen with HLA-DR3 common. |
|
|
Term
| Homogeneous/diffuse nuclear staining |
|
Definition
| chromatin, histone, maybe dsDNA antibodies |
|
|
Term
|
Definition
|
|
Term
| Speckled pattern of staining |
|
Definition
| most commonly .non-DNA antibodies. SM, ribonucleoprotein, SS-A/B antibodies |
|
|
Term
| Nucleolar Pattern of Staining |
|
Definition
|
|
Term
| Antibodies diagnostic of SLE |
|
Definition
|
|
Term
|
Definition
| keratoconjunctivitys sicca and xerostomia from immunologic destruction of glands. SS-A (ro) and SS-B (la) in many patients. Rh factor in 75%. HRHTLTV1. Appearance of a lymphoma. Previously Mikulicz disease. Lip biopsy diagnositic. |
|
|
Term
|
Definition
| Blurring of vision, burning, itching |
|
|
Term
|
Definition
| dysphagia, cracks/fissures in mouth, parotid gland enlargement. |
|
|
Term
|
Definition
| Systemic Sclerosis. Chronic inflammation, microvascular damage, perivascular fibrosis. Autoimmune. ANAs, nailfold capillary loops distorted. sclerodactyly, rubber-hose esophagus, GERD, malabsorption, malignant hypertension. pulmonary hypertension, pericarditis. Raynaud's, dysphagia, CREST |
|
|
Term
|
Definition
| calcinosis, reynaud, esophageal dysfunction, sclerodactyly, telangiectasia |
|
|
Term
|
Definition
| skin involvement at onset, rapid progression, early visceral involvement. |
|
|
Term
|
Definition
| confined to fingers, forearms, face. late visceral involvement. |
|
|
Term
|
Definition
| DNA topoisomerase I (Anti-Scl 70) is highly specific with more pulmonary fibrosis. Anticentromere antibody is less common and related to CREST |
|
|
Term
|
Definition
| necrotizing inflammation of the walls of blood vessels |
|
|
